FDA clears MRI-based AI tool to assess breast cancer recurrence risk
The FDA cleared an MRI-based AI tool in mid-October for assessing the risk of breast cancer recurrence.
Who is affected and how
- doctor
- Oncologists and radiologists may gain additional prognostic information from MRI to inform treatment decisions.
- medtech company
- The clearance reinforces the regulatory pathway for prognostic imaging AI.
Sources
- FDA clears AI tool for assessing breast cancer recurrence risk via MRIradiology business · Oct 19, 2026
- FDA Clears AI-powered, MRI-derived Prognostic Tool for Assessing Breast Cancer Recurrenceimaging technology news · Oct 19, 2026
- FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Canceronclive.com · Oct 19, 2026
- FDA clears AI tool to estimate breast cancer recurrence risk before surgery | Superpower Dailysuperpowerdaily.com · Oct 19, 2026
- FDA Clears MRI-Based Prognostic Tool for Recurrence Risk in HR-Positive Breast Cancer | ASCO AI in Oncologyascoai.org · Oct 19, 2026
- FDA Clears AI Tool Using MRI to Gauge Breast Cancer Recurrencecure today · Oct 20, 2026
- FDA Clears AI Tool Using MRI to Gauge Breast Cancer Recurrence | CUREcuretoday.com · Oct 20, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.